Interview: Calvin Chen, President, TWi Pharmaceuticals, Taiwan
Dr. Chen, you joined US-based Anchen Pharmaceuticals in 2009 to help the company form a spin-off in Taiwan. Why did…
TWi Pharmaceuticals, Taiwan
Last updated: 13.02.2014
Innovation, Integrity and IntegrationTWi Pharmaceuticals, Inc. headquartered in Taipei, Taiwan, is an emerging specialty pharmaceutical company focusing on the development, manufacturing and commercialization of high barrier generic prescription products, and new drug products that will fulfill unmet medical needs.
Established in April, 2010 as a result of spin-off by Anchen Inc. of the United States, TWi Pharmaceuticals, formerly Anchen Pharmaceuticals (Taiwan), Inc., was the research and development center and manufacturing base of Anchen Inc. in Taiwan. After the spin-off, TWi Pharmaceuticals maintains close relationships with Anchen Inc. and its subsidiary, Anchen Pharmaceuticals, Inc. in Irvine California, USA.
TWi Pharmaceuticals led by a team of dedicated and experienced managers and professionals who have had long and successful career in generic and brand pharmaceutical companies in United States and Asia. Prior to spin-off, TWi Pharmaceuticals using its highly innovative technologies of drug delivery and formulation developed in its Neihu R&D center has contributed in more than 20 Abbreviated New Drug Application (ANDA) submissions accepted by US FDA. Among the ANDA submissions, fifteen are filed with paragraph IV certification including five first to file that indicates no infringement of corresponding brand products and potential market exclusivity. Build upon the accomplishments, TWi Pharmaceuticals is targeting to file and obtain more ANDAs of high barrier generic drugs for US market. In addition, TWi Pharmaceuticals has obtained eight marketing approvals for Taiwan market.
4F, No. 41, Lane 221,
Kanh Chien Rd., Nei Hu Dist.
Taipei 114, Taiwan
Tel: 886-2-26573350
Fax: 886-2-26573391
E-mail: info@twipharma.com
http://www.twipharma.com/index.htm
Interviews
Related
Charles Chen – Vice Chairman & CEO, Medigen Vaccine Biologics Corp.…
Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s…
Johnsee Lee – Chairman & CEO & Eric Yang – VP, Quark…
Johnsee Lee and Eric Yang of Taiwanese precision medicine diagnostics firm Quark Biosciences outline their…
Louis Cheng – CEO, Leadgene Biomedical, Taiwan
Louis Cheng, CEO of Taiwanese firm Leadgene Biomedical, introduces the company’s expertise in antibody…
Johnsee Lee – Chairman, Taiwan Bio Industry Organization; President &…
Taiwan Bio Industry Organization Chairman Dr Johnsee Lee outlines the Taiwanese biopharmaceutical industry’s…
First Impressions / Taiwanese Pharma
Taiwan, although small in size, boasts a strong culture of innovation as well as a universal healthcare system that…
Report / New Taiwan Pharma Report November 2019 Out Now
Long overshadowed by larger and more well-known neighbours, the island of Taiwan is nonetheless cultivating an…
APAC / Taiwanese Pharma Looking Locally for International Opportunities
While Taiwanese pharmaceutical and biotech players have traditionally set their sights on the US as a key market,…
Talent / Multinationals' HR Strategies in Taiwan
All country managers of multinational pharma companies need to strike the balance between having a global outlook…
Stanley Huang – Founder & Managing Director, Nutrarex Biotech, Taiwan
Nutrarex Biotech is a Taiwanese private label contract manufacturer of functional supplements, exclusively…
APAC / Taiwan's New Southbound Policy: Enhancing Regional Ties
In an effort to enhance trade and cooperation with other countries in the region and reduce dependency on mainland…
Company Profile / iXensor, Taiwan
Within Taiwan’s evolving medical device sector, many innovative startups are exploring breakthrough ideas which…
Mark Yang – CEO, GaleMed, Taiwan
Mark Yang, CEO of GaleMed, elaborates on the medical device manufacturer’s transition from a privately-owned…
